Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15817696 | 1.00 | EHMT2 (0.41) | EHMT2P2RX7MEN1KMT2ACYP2C19 | |
| SCHEMBL15817697 | 1.00 | EHMT2 (0.41) | EHMT2P2RX7MEN1KMT2ACYP2C19 | |
| SCHEMBL698306 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL15818176 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL17314464 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL17314463 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL13270455 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL15818177 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL15818175 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL17314462 | 0.82 | ALDH1A1 (0.48) | EHMT2MEN1KMT2ACYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | EHMT2 82/4885P2RX7 3931/4885MEN1 2286/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | EHMT2 82/4885P2RX7 3931/4885MEN1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.